Australia's most trusted
source of pharma news
Saturday, 19 July 2025
Posted 17 July 2025 AM
A new dosing regimen with fewer side effects already used in Australia for Eli Lilly’s Alzheimer's disease drug Kisunla is now being rolled out in the US - and could have a positive impact on treatment uptake.
The updated FDA label, which is now in line with the label originally approved by the TGA in May 2025 involves a more gradual titration based on TRAILBLAZER-ALZ 6 study to lower the risk of amyloid-related imaging abnormalities with edema or effusion (ARIA-E).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.